← All Innate Pharma SA filings

Innate Pharma SA 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
IPHA
Innate Pharma SA
20-F: Innate Pharma Faces Going Concern Doubt Amid Program Shifts
Innate Pharma reported continued net losses and a limited cash runway, prompting a strategic refocus on key clinical assets and a significant organizational restructuring.
NASDAQ
IPHA
Innate Pharma SA
20-F: Innate Pharma Files 20-F, Reports Financial Results for Fiscal Year 2024
Innate Pharma files its annual report on Form 20-F, detailing its financial performance and business activities for the fiscal year ended December 31, 2024.
NASDAQ
IPHA
Innate Pharma SA
20-F: Innate Pharma Licenses Antibody Technology to Takeda in $415 Million Deal
Innate Pharma grants Takeda exclusive worldwide rights to develop antibody drug conjugates (ADCs) for celiac disease, receiving an upfront payment and potential milestones totaling $415 million.